will tirzepatide go back on shortage list FDA confirms is still over, gives compounders a grace period Update from Remedy Meds- still

These apps and their community sections range in cost from free to $59 per month

The introduction of new therapiesparticularly those with novel mechanisms of action or broader symptom coveragemay fragment prescriber preferences and intensify competition for patient share

In addition to mimicking the GLP-1 hormone, it also mimics the glucose-dependent insulinotropic polypeptide (GIP)

Naion is a rare eye disease that affects the optic nerve, causing sudden complete or partial loss of vision in one or, more rarely, both eyes

More recently, the SELECT trial (2023) showed a 20% reduction in MACE with semaglutide 2.4 mg in people with obesity without diabetes establishing it as the first weight-loss medication with proven cardiovascular benefit in this population

PubMed PMID: 33645410